A pitvarfibrilláció gyógyszeres kezelése.

Translated title of the contribution: Drug therapy of atrial fibrillation

Tamás Fazekas, Zoltán Csanádi, A. Varró

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The authors summarize the up-to-date knowledge relating to the pharmacological treatment of atrial fibrillation. They emphasize that drug treatment continues to be in the forefront of the therapy of the arrhythmia, which can now be considered to constitute a cardiovascular epidemic. In the era following the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AF-FIRM) trial, the strategy of pharmacological treatment will certainly change: in place of "rhythm control", which in recent decades has been overforced in patients identical with the elderly, cardiac patients with an impaired left ventricular function who were enrolled into AFFIRM, there will be a more frequent use of ventricular "rate control". Naturally, this does not mean that, in certain patient groups, an effort should not be made to restore and maintain the sinus rhythm. In cases involving congestive heart failure and structural heart disease complicated by a depressed left ventricular systolic function, atrial fibrillation is currently treated with antiarrhythmic drugs possessing low proarrhythmic activity that prolong refractory period (Class 3), and with the even safer mortality-reducing beta-receptor blockers. The classical antiarrhythmic drugs (quinidine, procainamide, disopyramide) are being increasingly forced into the background, and the areas of indication of the novel Na(+)-channel blocker antiarrhythmics (propafenone, flecainide) have also narrowed: they are administered only in the event of atrial fibrillation in patients with a structurally intact heart or left ventricular hypertrophy. After a brief survey of the more important aspects of ventricular rate control, and of the drugs available, the research trends aimed at the progression of the pharmacological treatment of atrial fibrillation are outlined. The clinical introduction of procedures based on myocardial gene therapy is now a realistic therapeutic approach as concerns atrial fibrillation too.

Original languageHungarian
Pages (from-to)1199-1206
Number of pages8
JournalOrvosi Hetilap
Volume144
Issue number24
Publication statusPublished - Jun 15 2003

Fingerprint

Atrial Fibrillation
Drug Therapy
Anti-Arrhythmia Agents
Pharmacology
Left Ventricular Function
Therapeutics
Propafenone
Flecainide
Disopyramide
Procainamide
Quinidine
Drug and Narcotic Control
Left Ventricular Hypertrophy
Genetic Therapy
Cardiac Arrhythmias
Heart Diseases
Heart Failure
Mortality
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fazekas, T., Csanádi, Z., & Varró, A. (2003). A pitvarfibrilláció gyógyszeres kezelése. Orvosi Hetilap, 144(24), 1199-1206.

A pitvarfibrilláció gyógyszeres kezelése. / Fazekas, Tamás; Csanádi, Zoltán; Varró, A.

In: Orvosi Hetilap, Vol. 144, No. 24, 15.06.2003, p. 1199-1206.

Research output: Contribution to journalArticle

Fazekas, T, Csanádi, Z & Varró, A 2003, 'A pitvarfibrilláció gyógyszeres kezelése.', Orvosi Hetilap, vol. 144, no. 24, pp. 1199-1206.
Fazekas T, Csanádi Z, Varró A. A pitvarfibrilláció gyógyszeres kezelése. Orvosi Hetilap. 2003 Jun 15;144(24):1199-1206.
Fazekas, Tamás ; Csanádi, Zoltán ; Varró, A. / A pitvarfibrilláció gyógyszeres kezelése. In: Orvosi Hetilap. 2003 ; Vol. 144, No. 24. pp. 1199-1206.
@article{3edbe92038034cdb96095f8679d137e4,
title = "A pitvarfibrill{\'a}ci{\'o} gy{\'o}gyszeres kezel{\'e}se.",
abstract = "The authors summarize the up-to-date knowledge relating to the pharmacological treatment of atrial fibrillation. They emphasize that drug treatment continues to be in the forefront of the therapy of the arrhythmia, which can now be considered to constitute a cardiovascular epidemic. In the era following the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AF-FIRM) trial, the strategy of pharmacological treatment will certainly change: in place of {"}rhythm control{"}, which in recent decades has been overforced in patients identical with the elderly, cardiac patients with an impaired left ventricular function who were enrolled into AFFIRM, there will be a more frequent use of ventricular {"}rate control{"}. Naturally, this does not mean that, in certain patient groups, an effort should not be made to restore and maintain the sinus rhythm. In cases involving congestive heart failure and structural heart disease complicated by a depressed left ventricular systolic function, atrial fibrillation is currently treated with antiarrhythmic drugs possessing low proarrhythmic activity that prolong refractory period (Class 3), and with the even safer mortality-reducing beta-receptor blockers. The classical antiarrhythmic drugs (quinidine, procainamide, disopyramide) are being increasingly forced into the background, and the areas of indication of the novel Na(+)-channel blocker antiarrhythmics (propafenone, flecainide) have also narrowed: they are administered only in the event of atrial fibrillation in patients with a structurally intact heart or left ventricular hypertrophy. After a brief survey of the more important aspects of ventricular rate control, and of the drugs available, the research trends aimed at the progression of the pharmacological treatment of atrial fibrillation are outlined. The clinical introduction of procedures based on myocardial gene therapy is now a realistic therapeutic approach as concerns atrial fibrillation too.",
author = "Tam{\'a}s Fazekas and Zolt{\'a}n Csan{\'a}di and A. Varr{\'o}",
year = "2003",
month = "6",
day = "15",
language = "Hungarian",
volume = "144",
pages = "1199--1206",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "24",

}

TY - JOUR

T1 - A pitvarfibrilláció gyógyszeres kezelése.

AU - Fazekas, Tamás

AU - Csanádi, Zoltán

AU - Varró, A.

PY - 2003/6/15

Y1 - 2003/6/15

N2 - The authors summarize the up-to-date knowledge relating to the pharmacological treatment of atrial fibrillation. They emphasize that drug treatment continues to be in the forefront of the therapy of the arrhythmia, which can now be considered to constitute a cardiovascular epidemic. In the era following the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AF-FIRM) trial, the strategy of pharmacological treatment will certainly change: in place of "rhythm control", which in recent decades has been overforced in patients identical with the elderly, cardiac patients with an impaired left ventricular function who were enrolled into AFFIRM, there will be a more frequent use of ventricular "rate control". Naturally, this does not mean that, in certain patient groups, an effort should not be made to restore and maintain the sinus rhythm. In cases involving congestive heart failure and structural heart disease complicated by a depressed left ventricular systolic function, atrial fibrillation is currently treated with antiarrhythmic drugs possessing low proarrhythmic activity that prolong refractory period (Class 3), and with the even safer mortality-reducing beta-receptor blockers. The classical antiarrhythmic drugs (quinidine, procainamide, disopyramide) are being increasingly forced into the background, and the areas of indication of the novel Na(+)-channel blocker antiarrhythmics (propafenone, flecainide) have also narrowed: they are administered only in the event of atrial fibrillation in patients with a structurally intact heart or left ventricular hypertrophy. After a brief survey of the more important aspects of ventricular rate control, and of the drugs available, the research trends aimed at the progression of the pharmacological treatment of atrial fibrillation are outlined. The clinical introduction of procedures based on myocardial gene therapy is now a realistic therapeutic approach as concerns atrial fibrillation too.

AB - The authors summarize the up-to-date knowledge relating to the pharmacological treatment of atrial fibrillation. They emphasize that drug treatment continues to be in the forefront of the therapy of the arrhythmia, which can now be considered to constitute a cardiovascular epidemic. In the era following the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AF-FIRM) trial, the strategy of pharmacological treatment will certainly change: in place of "rhythm control", which in recent decades has been overforced in patients identical with the elderly, cardiac patients with an impaired left ventricular function who were enrolled into AFFIRM, there will be a more frequent use of ventricular "rate control". Naturally, this does not mean that, in certain patient groups, an effort should not be made to restore and maintain the sinus rhythm. In cases involving congestive heart failure and structural heart disease complicated by a depressed left ventricular systolic function, atrial fibrillation is currently treated with antiarrhythmic drugs possessing low proarrhythmic activity that prolong refractory period (Class 3), and with the even safer mortality-reducing beta-receptor blockers. The classical antiarrhythmic drugs (quinidine, procainamide, disopyramide) are being increasingly forced into the background, and the areas of indication of the novel Na(+)-channel blocker antiarrhythmics (propafenone, flecainide) have also narrowed: they are administered only in the event of atrial fibrillation in patients with a structurally intact heart or left ventricular hypertrophy. After a brief survey of the more important aspects of ventricular rate control, and of the drugs available, the research trends aimed at the progression of the pharmacological treatment of atrial fibrillation are outlined. The clinical introduction of procedures based on myocardial gene therapy is now a realistic therapeutic approach as concerns atrial fibrillation too.

UR - http://www.scopus.com/inward/record.url?scp=0042697248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042697248&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 1199

EP - 1206

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 24

ER -